PCT & Support

Letrozole 2,5 mg Hilma Biocare

Hilma Biocare

65,00

In Stock (100 available)

Letrozole 2,5 mg Hilma Biocare (2,5 mg) — Hilma Biocare presents this pharmaceutical-grade compound — the most powerful aromatase inhibitor available, reducing estrogen l…

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

Letrozole 2,5 mg Hilma Biocare — letrozole from Hilma Biocare at 2.5 mg. Third-generation non-steroidal aromatase inhibitor — 2–5× more potent than anastrozole per mg. Reserved for heavy cycles or gynaecomastia reversal.

Key Benefits

  • Most potent aromatase inhibitor in clinical use
  • Reserved for aggressive E2 control or gyno rescue protocols
  • 98%+ aromatase inhibition at standard doses
  • Easy to over-suppress — titration with bloodwork essential
  • Not a first-line on-cycle AI — anastrozole or exemestane preferred
  • Each unit dosed at 5 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: 0.5–1.25 mg every other day for aggressive E2 management; 2.5 mg daily for 10–14 days for gyno rescue. Start low — letrozole crashes E2 fast. Bloodwork at 2 weeks mandatory.

How It Works

Non-steroidal aromatase inhibitor. Achieves ~98% aromatase inhibition at therapeutic doses (vs anastrozole ~85%). Reversible binding. Used clinically for breast cancer; off-label in AAS protocols for aggressive cycles or gyno reversal.

Pharmacokinetics

Plasma half-life approximately 2 days. Every-other-day or daily dosing depending on target. Steady-state in 10 days.

Potential Side Effects

Signature risk: crashed E2 with joint pain, libido loss, fatigue. Lipids can take a bigger hit than anastrozole. Use only when less potent AIs are insufficient.

Cycle & Stacking Guide

Reserved for aggressive E2 management or gyno rescue. Typical use: week 1–2 at 2.5 mg/day to reverse active gyno, then transition to anastrozole maintenance. Not a first-line on-cycle AI.

Manufacturer Notes

Hilma Biocare operates a Romanian GMP site with dedicated HPLC bays. Their catalogue emphasises clean oil carriers (often MCT or ethyl oleate) to reduce post-injection pain.

Storage & Handling

Store in the original blister or bottle at 15–25 °C, away from direct sunlight, heat, and humidity. Oral preparations lose potency faster if exposed to moisture; keep the desiccant (if included) with the tablets. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Letrozole 2,5 mg Hilma Biocare”

Your email address will not be published. Required fields are marked *

Letrozole

Physical & Chemical Properties for Research Purposes
Chemical structure of Letrozole (C17H11N5) for laboratory analysis
2D structural representation · PubChem CID 3902 ↗
Chemical Identity
# CAS Registry Number 112809-51-5
Σ IUPAC Name 4,4'-(1H-1,2,4-triazol-1-ylmethylene)dibenzonitrile
F Molecular Formula C17H11N5
M Molecular Weight 285.30 g/mol
SMILES N#CC1=CC=C(C=C1)C(N2C=NC=N2)C3=CC=C(C=C3)C#N
InChIKey HPJKCIUCZWXJDR-UHFFFAOYSA-N
Melting Point 181-183 °C
Solubility Freely soluble in dichloromethane; slightly soluble in ethanol; practically insoluble in water
Biological Half-life 2 days (oral)
PubChem CID 3902 ↗
Pharmacological Profile
Aromatization None
Hepatotoxicity Low
Known trade names: Femara, Letrozol, Femar

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.